GO
Loading...

Pharmaceuticals

More

  • NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..

  • Aug 5- Generic drug maker Actavis Plc's full-year profit forecast missed analysts' estimates, sending its shares down about 3 percent in premarket trading. Actavis said it expects profit of $13.02- $13.32 per share for the year ending x, below Wall Street estimates of $13.73 per share. Excluding items, Actavis earned $3.42 per share in the second quarter.

  • Gaining access to experimental drugs     Tuesday, 5 Aug 2014 | 7:44 AM ET

    Scott Gottlieb, M.D., American Enterprise Institute, and Jeff Allen, Friends of Cancer Research executive director, discuss the FDA's drug approval process and the need in some cases to allow access to experimental therapies.

  • Drugmaker Actavis posts 34 pct rise in revenue Tuesday, 5 Aug 2014 | 7:36 AM ET

    Aug 5- Generic drug maker Actavis Plc's quarterly revenue rose 34 percent due to strong growth in its North America business. The company had a net profit of $48.7 million, or 28 cents per share, attributable to shareholders for the second quarter ended June 30. Excluding items, Actavis earned $3.42 per share in the second quarter.

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • Bill Ackman

    A lawsuit by Allergan says the unusual arrangement by Valeant Pharmaceuticals and activist investor Bill Ackman amounts to insider trading.

  • An Ebola vaccine? 'There's no money in it.' Monday, 4 Aug 2014 | 10:56 AM ET
    Medical staff put on protective gear at Kenema Government Hospital before taking a sample from a suspected Ebola patient in Kenema, Sierra Leone.

    The death toll from the Ebola virus in West Africa keeps growing to record levels. And ironically, that may be why there's no vaccine, said an expert.

  • Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..

  • Aug 1- Botox maker Allergan Inc on Friday accused rival Valeant Pharmaceuticals International and billionaire investor William Ackman of violating securities laws by using insider information as they prepared a takeover bid for the drug company.

  • Africa escalates fight against Ebola as cases surge Friday, 1 Aug 2014 | 11:17 AM ET

    West African leaders and international health groups have stepped up plans to combat the world’s worst outbreak of the deadly Ebola virus.

  • MUMBAI, Aug 1- Pfizer Ltd, the Indian unit of U.S. drugmaker Pfizer Inc, said on Friday it locked out staff at its Mumbai drug factory after some employees tried to disrupt production lines and threatened management.

  • Catalent CEO: Leading advanced drug delivery     Thursday, 31 Jul 2014 | 11:30 AM ET

    John Chiminski, Catalent Pharma Solutions CEO, discusses the company's IPO and business strategy. Chiminski the company is the world's leader in advanced drug technologies.

  • *Q2 EPS ex-items $1.23 vs $1.22 forecast. *Now sees 2014 EPS $4.50- $4.80 with Copaxone competition. TEL AVIV, July 31- Teva Pharmaceutical Industries raised its full-year profit forecast on Thursday after posting higher quarterly earnings that were due in part to the launch of several generic products in the United States.

  • JERUSALEM, July 31- Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • PARIS, July 31- French drugmaker Sanofi raised its full-year profit forecast on Thursday along with a set of stronger than expected quarterly earnings driven by its rare disease and diabetes businesses and higher sales in emerging markets.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • July 30- Israeli drugmaker Teva Pharmaceuticals Industries said on Wednesday it turned back efforts by Israeli industrialist Benny Landa to shake up the company's board of directors, with shareholders approving all of the company's proposals and board nominations.

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • Hospira beats profit estimates, raises 2014 outlook Wednesday, 30 Jul 2014 | 7:58 AM ET

    July 30- Hospira Inc, a pharmaceutical and medical device maker, posted a better-than-expected quarterly profit on higher sales of specialty injectable drugs, and raised its full-year outlook.